OTLK Share Price Performance
US$1.93
-5.12 (-72.62%)
Price US$1.93
RedBaronRick
Share PriceUS$1.93
OTLK Community Narratives
RE
Fair Value US$0 n/aintrinsic discount
Outlook Therapeutics will stay static with a 0% revenue change in the 5-year forecast
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
OTLK Community Fair Values
- RECommunity Contributor
Outlook Therapeutics will stay static with a 0% revenue change in the 5-year forecast
Rests on the FDA. With that said, OTLK was close to approval last round...US$0FVn/aintrinsic discount0%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative1users have followed this narrativeabout 1 month ago author updated this narrative
Recent OTLK News & Updates
No updates
Outlook Therapeutics, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 0.49
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- -101.8%
Outlook Therapeutics, Inc. Competitors
About OTLK
- Founded
- 2010
- Employees
- 23
- CEO
- WebsiteView website
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Iselin, New Jersey.
U.S. Market Performance
- 7 Days: -2.7%
- 3 Months: 11.4%
- 1 Year: 20.5%
- Year to Date: 5.9%
Over the last 7 days, the market has dropped 2.7%, driven by a decline of 2.4% in the Information Technology sector. As for the longer term, the market has actually risen by 20% in the last year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading